Dr. Christina Baik on Alectinib Versus Crizotinib in ALK-positive Lung Cancer

Christina Baik, MD, MPH, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer.

Christina Baik, MD, MPH, assistant professor, Seattle Cancer Care Alliance, Thoracic/Head and Neck, Department of Medicine, Division of Medical Oncology, University of Washington, discusses alectinib compared to crizotinib in the first-line setting for patients with ALK-positive lung cancer. Baik says there was a recent trial comparing the two drugs head-to-head, and results from the trial should be available soon.